•
Dec 31, 2024

Turning Point Brands Q4 2024 Earnings Report

Turning Point Brands reported strong revenue growth in Q4 2024, with increased sales in both Zig-Zag and Stoker’s product segments, despite a decline in net income due to one-time discontinued operations losses.

Key Takeaways

Turning Point Brands delivered strong Q4 2024 results, with total revenue increasing by 12.8% year-over-year to $93.67 million. Zig-Zag product sales grew modestly, while Stoker’s segment saw significant gains, driven by increased volume and favorable pricing. Net income declined due to a one-time $7.3 million loss from discontinued operations, but adjusted net income rose by 12.7% to $18 million. Adjusted EBITDA increased by 5.3% to $26.2 million, reflecting continued operational efficiency and growth in key product lines.

Q4 2024 revenue increased 12.8% year-over-year to $93.67 million.

Net income declined 76.1% to $2.4 million due to discontinued operations losses.

Stoker’s Products segment net sales grew 25.8%, while Zig-Zag net sales rose 1.8%.

Adjusted EBITDA increased by 5.3% to $26.2 million.

Total Revenue
$93.7M
Previous year: $97.1M
-3.6%
EPS
$0.98
Previous year: $0.79
+24.1%
Smokeless Volume Growth
17.8%
Previous year: 14.2%
+25.4%
Smokeless Price/Mix Growth
8%
Previous year: 4.4%
+81.8%
Zig-Zag cones outlets
220K
Gross Profit
$52.4M
Previous year: $50.5M
+3.7%
Cash and Equivalents
$46.2M
Previous year: $118M
-60.8%
Free Cash Flow
$16.6M
Previous year: $22.9M
-27.5%
Total Assets
$493M
Previous year: $569M
-13.3%

Turning Point Brands

Turning Point Brands

Turning Point Brands Revenue by Segment

Forward Guidance

Turning Point Brands expects strong performance in 2025, with projected adjusted EBITDA between $108 million and $113 million. The company also anticipates Modern Oral product sales reaching $60 million to $80 million, driven by continued expansion and product adoption.

Positive Outlook

  • Projected adjusted EBITDA growth to $108-$113 million for FY 2025.
  • Modern Oral product sales expected to reach $60-$80 million.
  • Strong momentum in Stoker’s MST and Modern Oral segments.
  • Improved operational efficiencies leading to higher margins.
  • Successful launch of new product innovations in key markets.

Challenges Ahead

  • Potential regulatory challenges impacting Modern Oral product approvals.
  • Continued pressure on Zig-Zag gross margins due to product mix changes.
  • Macroeconomic uncertainties affecting consumer demand.
  • Rising SG&A expenses due to restructuring and compliance costs.
  • Increased competition in the alternative tobacco and smoking accessories markets.

Revenue & Expenses

Visualization of income flow from segment revenue to net income